3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
41
Carcinoma, Non-Small-Cell Lung
28
Lung Neoplasms
8
Triple Negative Breast Neoplasms
6
Neoplasm Metastasis
6
Neoplasms
5
Uterine Cervical Neoplasms
4
Recurrence
2
Mesothelioma
2
Lymphoma, Non-Hodgkin
2
Carcinoma
2
Adenocarcinoma of Lung
2
Adenocarcinoma
2
Thoracic Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Nonhematologic Malignancies
1
Non-Squamous Non-Small Cell Lung Cancer
1
Non - Small Cell Lung Cancer NSCLC
1
Neuroendocrine Tumors
1
NSCLC
1
Metatropic dwarfism
1
Metastatic HER2-positive Breast Cancer
1
Lung Diseases
1
Lethal Congenital Contracture Syndrome 2
1
HR+HER2- Breast Cancer
1
HER2-positive Advanced Breast Cancer
1
Desmoplastic Small Round Cell Tumor
1
Interventions
pembrolizumab
180
Cisplatin
44
Paclitaxel
41
Carboplatin
41
lenvatinib
31
Docetaxel
22
Pemetrexed
20
Fluorouracil
19
Capecitabine
16
Gemcitabine
15
Saline Solution
13
Oxaliplatin
13
Albumin-Bound Paclitaxel
10
epacadostat
9
130-nm albumin-bound paclitaxel
9
Leucovorin
8
Cetuximab
8
olaparib
7
Irinotecan
7
Bevacizumab
7
Etoposide
6
belzutifan
5
Dexamethasone
5
enzalutamide
4
trifluridine tipiracil drug combination
3
regorafenib
3
patritumab deruxtecan
3
enfortumab vedotin
3
durvalumab
3
Surgical Procedures, Operative
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Vinorelbine
×
Clear all
NCT02555657
2021-12-10
KEYNOTE-119
Merck Sharp & Dohme LLC
Phase 3
Completed
622 enrolled
26 charts